A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. (Q33358093)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14669278%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813 (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14669278%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

based on heuristic

inferred from title

prostate carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14669278%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14669278%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

author name string

W Kevin Kelly

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14669278%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Cary Werner

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14669278%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Paul A Godley

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14669278%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Nicholas J Vogelzang

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14669278%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Eric J Small

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14669278%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Cancer and Leukemia Group B 99813

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14669278%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

language of work or name

0 references

publication date

1 December 2003

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14669278%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14669278%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

98

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14669278%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14669278%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

2592-2598

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14669278%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Hormone-refractory prostate cancer: a multi-step and multi-event process

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11829

7 January 2021

based on heuristic

inferred from DOI database lookup

MANAGEMENT OF HORMONE REFRACTORY PROSTATE CANCER: CURRENT STANDARDS AND FUTURE PROSPECTS

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11829

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11829

7 January 2021

based on heuristic

inferred from DOI database lookup

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11829

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy for prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11829

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11829

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11829

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11829

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11829

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11829

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of carboplatin on response and palliation in hormone-refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11829

7 January 2021

based on heuristic

inferred from DOI database lookup

A critical analysis of response criteria in patients with prostatic cancer treated with CIS-diamminedichloride platinum II

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11829

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11829

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11829

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11829

7 January 2021

based on heuristic

inferred from DOI database lookup

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11829

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11829

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.11829

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14669278%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

release_dvwzphdxzzehhengymxubkqwrq

1 reference

https://api.fatcat.wiki/v0/release/dvwzphdxzzehhengymxubkqwrq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:14669278%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33358093&oldid=2049920010"